Prelude Therapeutics Inc
Close on Oct 19, 2026
- Market cap
- $333.54M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | $-0.14 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 10, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | $6.50M | $-0.26 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | During market hours | – | $-0.42 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 10, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 15, 2024 | During market hours | – | – | – |
Press releases
Announcements Prelude Therapeutics filed with the SEC
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation September 2026 Exhibit 99.2
Regulation FD disclosure · EX-99.2 to Form 8-K
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation May 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
“forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated discovery, preclinical and clinical
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation March 2026 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation JANUARY 2026 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation November 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
PRESS RELEASE ANNOUNCING EXCLUSIVE OPTION AGREEMENT WITH INCYTE, DATED NOVEMBER 4, 2025
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
PRESS RELEASE ANNOUNCING STRATEGIC BUSINESS UPDATE, DATED NOVEMBER 4, 2025
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
CORPORATE PRESENTATION, DATED NOVEMBER 4, 2025
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation August 2025 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation May 2025 Update Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Prelude Announces Presentations at 2025 AACR Annual Meeting
Other events · EX-99.1 to Form 8-K
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation March 2025 Update Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation November 2024 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36 th EORTC-NCI-AACR Symposium
Other events · EX-99.1 to Form 8-K
Corporate Presentation October 2024 Exhibit 99.2
Other events · EX-99.2 to Form 8-K
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Other events · EX-99.1 to Form 8-K
PRT3789 Phase 1 Interim Clinical Data Update from 2024 ESMO Congress 13 September 2024 Investor Presentation Exhibit 99.2
Other events · EX-99.2 to Form 8-K
Corporate Presentation September 2024 Exhibit 99.3
Other events · EX-99.3 to Form 8-K
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation August 2024 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Prelude’s First-in-Class, Highly Selective SMARCA2 Degraders PRT3789 (IV) and PRT7732 (Oral) Click Here to Access Prelude’s Educational Video Series on SMARCA2 Degraders
Regulation FD disclosure · EX-99.1 to Form 8-K
Dr. Timothy Yap, University of Texas MD Anderson Cancer Center Advancing our Understanding of SMARCA Science
Regulation FD disclosure · EX-99.2 to Form 8-K
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Prelude Therapeutics Reports Full Year 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K